GlassScriptPhysician profile
Howard Bruce Gerber
NPI 1003876285
$12,586.10
in general payments reported to CMS, 2019-2025
30 companies · $2,230 in 2025
The $2,230 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,386 · 2020: $979 · 2021: $1,463 · 2022: $2,011 · 2023: $2,226 · 2024: $2,291 · 2025: $2,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,738 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,737.81 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,552.71 | 2019-2025 | |
| Janssen Biotech, INC. | $938.67 | 2019-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $892.98 | 2023-2025 | Zoryve |
| Allergan, INC. | $884.23 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $714.39 | 2019-2025 | Ilumya |
| Genzyme Corporation | $678.13 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $630.26 | 2019-2025 | |
| Lilly USA, LLC | $594.94 | 2021-2025 | Taltz, Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $592.40 | 2019-2025 | Cabtreo, Siliq, Altreno |
| Pfizer INC. | $532.33 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $464.03 | 2022-2023 | Sotyktu |
| Dermavant Sciences, INC. | $342.93 | 2023-2024 | Vtama |
| Amgen INC. | $279.01 | 2021-2023 | Otezla |
| Galderma Laboratories, L.P. | $275.75 | 2019-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $265.21 | 2020-2025 | Dupixent |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $158.97 | 2022-2025 | Bimzelx |
| Mayne Pharma Commercial LLC | $152.92 | 2019-2025 | |
| Almirall LLC | $149.17 | 2021-2023 | Klisyri |
| Organon LLC | $87.14 | 2025 | Vtama |
| Biofrontera INC. | $83.78 | 2019-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.45 | 2024-2025 | Spevigo |
| Leo Pharma INC. | $69.66 | 2020-2025 | Anzupgo, Adbry |
| Celgene Corporation | $66.61 | 2019 | |
| Genentech USA, INC. | $19.98 | 2021 | |
| Fidia Pharma USA INC. | $17.92 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $17.20 | 2019 | |
| Incyte Corporation | $14.33 | 2022 | |
| Vyne Pharmaceuticals INC. | $13.87 | 2020 | |
| Dermira, INC. | $12.28 | 2021 | |
| Solta Medical, A Division of Bausch Health US, LLC | $11.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Gerber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.